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Abstract

GENERATION OF MACROPHAGE CHEMOTACTIC FACTORS BY sPLA2
By Andria Chambers, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Suzanne E. Barbour, Ph.D.
Professor, Department of Biochemistry and Molecular Biology

Removal of apoptotic cells by macrophages is required in order to prevent autoimmune
responses. Previous studies have reported that group IIA secretory phospholipase A2
(sPLA2) preferentially binds to apoptotic cells and induces a chemotactic factor which
promotes the migration of macrophages to apoptotic cells. Based on these observations,
we hypothesized that the pool of sPLA2 trapped on apoptotic cells produces
chemoattractant lipids that recruit macrophages to phagocytose the apoptotic cells. To test
this hypothesis, Jurkat cells were cultured under normal conditions and induced to undergo
early apoptosis through treatment with D,L-threo-dihydrosphingosine. Live and early
apoptotic cells were incubated with catalytically active sPLA2 and then cell-associated
vii

catalytic activity was assessed. In contrast to previous reports, we observed no difference
in the ability of live or early apoptotic cells to trap group IIA sPLA2 on their surfaces.
However, transmigration assays involving THP-1 monocytes confirmed that the cell-bound
pool of sPLA2 generates chemoattractants when bound to the surfaces of live cells.
Surprisingly, sPLA2 does not have to be catalytically active to attract THP-1 monocytes.
The treatment of live Jurkat cells with heparinase showed a marked reduction in the ability
of sPLA2 to bind to live cells and exert catalytic activity, suggesting heparan sulfate
proteoglycans are possibly receptors for sPLA2. Future experiments are being planned to
identify sPLA2 receptor(s) on THP-1 monocytes.
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Introduction
Apoptosis, or programmed cell death, was given its distinct name in 1972 by John
Kerr, Andrew Wilie, and Alastair Currie when they noticed distinct morphological changes
observed in a wide variety of cell types that underwent a unique kind of cell death differing
from necrosis (1). Apoptosis occurs in all multi-cellular organisms and is usually seen
during the development of infections, wound healing, or in diseased areas. Apoptosis is
characterized by many biochemical and morphological changes such as dramatic
perturbations to the cellular architecture which contribute to cell death and prepare the
dying cells for removal by phagocytes. The removal by phagocytes prevents unwanted
immune responses (2). Some classic characteristics of apoptosis are cell shrinkage, DNA
fragmentation, cytoplasmic condensation, dramatic condensation of nuclear
heterochromatin, dislocation of the endoplasmic reticulum, cell surface blebbing, and loss
of phospholipid asymmetry (1, 2).
The best characterized change in cells undergoing apoptosis is the loss of
phospholipid asymmetry and the translocation of phosphatidylserine (PS) from the inner
leaflet of the phospholipid bilayer to the outer leaflet. This process occurs very early in
apoptosis and forms a signal to be recognized by phagocytes and other types of activated
macrophages (3). The PS exposure and ultimate recognition by phagocytes suggests that
the lipid is not ordinarily seen on the plasma membrane surface. PS makes up about 2-
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10% of the lipids in the plasma membrane in most eukaryotic cells, and in healthy cells
nearly all of the PS is on the inner leaflet of the plasma membrane (5). Phosphatidylserine
is normally kept from the surface of T-lymphocytes by ATP dependent internalization
mediated by an aminophospholipid translocase. The enzyme has the unique ability to
move phosphatidylserine and phosphatidylenolamine (with less efficiency) to the outer cell
interior (4). Down regulation of the translocase and activation of a lipid scramblase allows
for PS exposure on the cell surface before DNA degradation, membrane blebbing, and cell
lysis. Though PS exposure is very important, it may not necessarily be significant enough
for uptake by phagocytosis; there are many changes in the expression of membrane
associated markers. Other kinds of recognition signals produced on the surface of
apoptotic cells are exposure of a ligand for the vitronectin receptor; exposure of the
phosphocholine functional group on membrane phosphatidylcholine; changes in the
surface charge of the glycoproteins and lipids; binding of thrombospondin; and expression
of intercellular adhesion molecule III (5). Clearance of apoptotic cells is a complex
process where many surface molecules, adaptors, and chemotactic molecules are involved
but it is not necessary that all of the recognition signals are expressed or that all receptors
are required to mediate engulfment.
The process of apoptotic cell engulfment can be divided into broad steps: sensing
the presence of the apoptotic cells; recognition of the apoptotic cells by the phagocyte;
cytoskeletal reorganization and internalization of the target; processing and degradation of
the ingested apoptotic cell; and post engulfment responses of the phagocyte (5). Apoptosis
normally leads to swift engulfment by professional (macrophages and immature dendritic
2

cells) and non professional phagocytes (endothelial cells, fibroblasts, smooth cells,
epithelial cells). Certain receptors on activated macrophages such as phosphatidylserine
receptors, CD14, lectins, integrins, asialoglycoprotein receptors, and more specifically a
vitronectin receptor that cooperates with CD36 on human monocyte-derived macrophages
which binds to thrombospondin on apoptotic cells (25). These receptors in turn can assist
in attracting phagocytes to apoptotic cells. Phagocytes can engulf apoptotic cells and use
a major histocompatibility complex anchored in the cell membrane to display the degraded
polypeptides on their surface to T cells via T cell receptors. The MHC peptide complex
binds with ligands for antigen receptors on T cells and regulates T cell activity (4). The
surrounding tissues are protected from pro-inflammatory cell contents, such as TNF-α and
IFN-γ. The pro-inflammatory cell contents can ultimately leak and cause accidental cell
death, or necrosis. Apoptotic cells that are cleared promptly exhibit immune tolerance
which can also be attributed to the presence of anti-inflammatory contents such as TGF-β
and PGE2 (25). Apoptosis needs to be complemented by a swift removal of the apoptotic
cell corpse. The recognition signals ensure the efficient removal of apoptotic cells to
prevent post-apoptotic necrosis. If a cell dies by necrosis or if an apoptotic cell fails to be
cleared and undergoes a secondary kind of necrosis, the intracellular contents are released,
T cells are activated, and harmful inflammatory responses are produced (6).
Before an apoptotic cell can be phagocytosed, an activated monocyte needs to
migrate to the dying cell. There has been evidence that apoptotic clearance by phagocytes
is regulated by endogenously produced mediators released by dying cells. Apoptotic cells
are known to secrete chemotactic factors that stimulate the attraction of monocytic cells
3

and macrophages and facilitate apoptosis (3,6). The phospholipase A2 (PLA2) family is
characterized as enzymes that have the ability to catalyze the hydrolysis of the sn2- fatty
acyl bond position of phospholipids to release free fatty acids and lysophospholipids. The
resulting products are the suggested lipid mediators that induce monocyte chemotaxis to
dying cells (7). An activated calcium independent phospholipase (iPLA2) has been shown
to generate chemotactic factors in a caspase-3 dependent fashion, but other types of
phospholipases have been shown to generate monocyte chemotaxis to dying cells either
directly or indirectly also (6). Our focus will be on secretory phospholipase A2 (sPLA2)
and its ability to generate chemotactic factors on apoptotic cells. We will also try to
identify a possible sPLA2 receptor that aids in trapping the enzyme on cell surfaces.
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Phospholipases

The phospholipase A2 (PLA2) family catalyzes the hydrolysis of the sn-2 position of
membrane glycerophospholipids to liberate free fatty acids and lysophospholipids involved
in the regulation of both physiological and pathological processes. The common fatty
acids released by hydrolysis are arachidonic acid (AA) and oleic acid (OA), which are
important stores of energy. Arachidonic acid can function as a messenger and precursor of
various bioactive pro-inflammatory compounds called eicosanoids (including
prostaglandins, thromboxanes, lipoxins, and leukotrienes) known to mediate inflammation
and signal transduction. Lysophospholipids, such as lysophosphatidic acid (LPA) and
lysophosphatidylcholine (LPC), are important in cell signaling, phospholipid remodeling,
and membrane perturbation (8, 9). Lysophospholipids are biologically active by
themselves and are precursors of other bioactive mediators like platelet activating factor
(PAF). Phospholipase A2 is involved in many different cellular processes such as
phospholipid digestion and metabolism, host defense, and signal transduction. The
actions of PLA2’s can also be important for down regulating cell signals, as seen with
PLA2 catalyzed hydrolysis of platelet activating factor to its inactive lysophospholipid
form. PLA2 activity was first studied in pancreatic juice and cobra venom but has recently
been studied in humans (7).
Presently, 19 different isoforms of PLA2 enzymes have been identified. The
various enzymes can be broken down into groups based the location of the enzymes; the
enzymes are classified as either an extracellular secreted enzyme or an intracellular
5

cytosolic enzyme (10). Phospholipase A2 can also be divided into three different
categories based on their calcium dependence and other properties: cytosolic PLA2
(cPLA2), secretory PLA2 (sPLA2), and calcium independent PLA2 (iPLA2). Cytosolic
PLA2 requires micromolar levels of calcium and is found intracellularly. sPLA2 requires
millimolar levels of calcium and is found extracellularly while iPLA2 is completely
independent of calcium for their activities, but like cPLA, is found intracellularly (11).
Cytosolic PLA2 (cPLA2) enzymes are very important in the initiation of AA
metabolism and are found to be the most prevalent and the most well studied of the
cytosolic enzymes (9,10). Activation of cPLA2 is regulated by micromolar calcium
binding of cPLA2 to the cell membrane for access to phospholipid substrate (due to a C-2
domain located in the N-terminus of the enzyme) and phosphorylation by MAP kinases.
Both are important in the post-receptor signaling transduction. This is the only enzyme
family that shows a preference for AA over the other fatty acids for the hydrolysis of the
sn-2 position of phospholipids (9,12). Cytosolic PLA2’s are also characterized as having a
catalytic serine that forms an acyl ester intermediate during hydrolysis, which is eventually
broken down by a water molecule. According to the Dennis classification, cPLA is also
known as group IV and has six isoforms that are ubiquitously expressed and lack disulfide
bonds. They are known as cPLA2-α, cPLA2-β, and c-PLA2-γ, c-PLA2-δ, c-PLA2-ε, and cPLA2-ζ. Each are characterized as typically having a large molecular weight ranging from
61-114 kDa but mainly found to be around 85kDa (12).
Calcium independent PLA2, classified as group VI, is the most recently identified
category of phospholipases A2 and is known as iPLA2. These cytosolic enzymes are found
6

in multiple splicing variations and tend to be associated with apoptosis and phospholipid
remodeling. Calcium is not required for catalysis in iPLA2 and like cPLA they also do not
possess disulfide bonds (9). iPLA2 has a higher molecular weight than cPLA of around 84
to 88 kDa and the enzyme also possesses a catalytic serine, but its structure is very
different from the cPLA2 family (1).
Secreted phospholipase A2 (sPLA2) was originally found in large amounts in
porcine pancreas. The enzyme family, consisting of 11 isozymes identified so far, have a
low molecular weight (14 to 17 kDa), and are calcium requiring (mM) secretory enzymes
that have been implicated in a number of biological processes such as eicosanoid
generation, inflammation, and host defense. The extracellular enzyme was also found to
be highly disulfide bonded and having a catalytic histidine residue (8). The seven disulfide
bonds (and up to two additional unique disulfide bonds) in the sPLA2 family are highly
conserved, which allows the enzyme to be highly stable (9). Secreted PLA2’s do not form
a classical acyl enzyme intermediate characteristic of serine proteases, nor do they display
any specificity for arachidonic acid in the phospholipids sn-2 position. They use the
catalytic site histidine, assisted by an aspartate to polarize a bound water molecule, which
will then attack the carbonyl group. The required calcium ion (needed in millimolar
concentrations), which is bound in the conserved calcium binding loop, ultimately
stabilizes the transition state (7).
The proposed general catalytic cycle for sPLA2 goes as follows: The enzyme
partitions from the aqueous phase to the bilayer interface; the enzyme undergoes an
allosteric activation; catalysis commences; and products are released. Water soluble
7

enzymes, such as sPLA2, can reversibly interact with membranes and catalyze reactions at
the interface of an aqueous solution and lipid surface (14). When sPLA2 is in aqueous
solution, its calcium containing catalytically active site is buried in a channel lined with
hydrophobic amino acids. Partition from the aqueous phase to the phospholipid interface is
critical for catalysis; catalysis in aqueous phase is nonexistent (14,15). Specifically, for
group IIA sPLA2, the enzyme binds with highest affinity to bilayers composed of
negatively charged phospholipids. This phenomenon is driven in part by electrostatic
interactions caused because the rim of the positively charged lysine and arginine residues
around the entrance to the catalytically active channel is attracted to the negatively charged
polar groups (anionic phospholipids such as PS and PE found on the outer leaflet during
early apoptosis) in the lipid membrane (important in interfacial binding) (16) The cationic
residues closest to the opening of the active site slot make the most important interactions
with the membrane. Binding of the enzyme to the lipid membrane induces a
conformational change in the phospholipase. A substrate molecule must leave the
membrane to travel into the catalytically active site (14, 15). Binding strength to
phospholipid heads is increased and a hydrophobic channel containing the active site opens
allowing the phospholipid molecule to move from the bilayer to inside the channel. The
calcium located in the channel binds to the head group of the substrate positioning the ester
bond to be hydrolyzed next to the catalytic site by a water molecule (15,16). The
catalytically active histidine, characteristic of sPLA2, in turn activates a water molecule to
hydrolyze the ester bond producing free fatty acids and lysophospholipids (17).
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The most abundant phospholipase A2 group found in human tissues is sPLA2 group
IIA (sPLA2 IIA) (12). Group IIA PLA2 is known mainly for its role in inflammation
because it has been shown to be highly expressed in human and rat tissue related to
immune responses. Group IIA’s signaling properties are generated as a result of the
biological activity of unesterified fatty acids and lysophopholipids it produces, as well as
IIA’s ability to perturb cellular membranes by interacting with phospholipids, the ability to
interact with membrane receptors analogous to those binding other sPLA2’s, and the ability
to bind heparan sulfate proteoglycans. Group IIA can release the bioactive compound
arachidonic acid and produce other eicosanoids via cycloxygenase or lipoxygenase
enzymes (prostaglandins and leukotrienes) during inflammatory conditions such as
ateriosclerosis, septic shock, and rheumatoid arthritis (10). The other reaction products
generated, lysophosphatidic acid (LPA) or lysophosphatidylcholine (LPC), are also
biologically active by themselves and are the precursors of other potent bioactive
mediators such as platelet-activating factor (PAF); all of which are known to be potent
monocyte chemoattractants (9). IIA is highly cationic and binds tightly to anionic
heparanoids such as heparan and heparan sulfate. Cell surfaces are usually rich in heparan
sulfate proteoglycans (HSPG) and significant portions of IIA are present in a membrane
bound form rather than secreted extracellularly when expressed in mammalian cells (9).
Following binding to HSPG, a number of endocytic routes are available to allow
internalization of group IIA where the enzyme may be allowed to hydrolyze phospholipids.
Group IIA has shown great pathophysiological potential because many of its biological
actions depend on interactions with receptors similar to those involved in the toxic effects
9

of PLA2 found in venoms. IIA is able to behave as a ligand for a group of receptors that
are part of the c-type multilectin mannose receptor family. The receptors, named N-type
(neuronal) and M-type (muscle), help the enzyme internalize to specific compartments
within cells where they release AA or other bioactive lipids, which produce biological
responses (12, 23). Unfortunately, the IIA sPLA2 from the mouse is the only kind of IIA
found to bind to the M-type receptor suggesting that there are possibly other receptors
involved in binding the human form of IIA sPLA2.
Recent studies have shown that apoptotic cells induce chemotactic factors in a
caspase-3 dependent function via activation of the intracellularly located phospholipase A2,
iPLA2. The activation of iPLA2 was required for the release of the chemotactic factor
lysophosphatidylcholine which was found to be important in the migration of monocytes to
apoptotic cells. Secretory phospholipase A2 is also able to generate the production of LPC
from the hydrolysis of anionic phosphatidylcholine located on the membrane of cells that
have undergone apoptosis (6). Boilard suggested that the highly cationic group IIA sPLA2
binds with high affinity to cells undergoing apoptosis because of an increase in exposed
anionic phospholipids on the outer leaflet of the phospholipid membrane and perturbed
membrane asymmetry (18). Even though once cells have become apoptotic, they have an
increased attraction to the action of group IIA, the membrane asymmetry of apoptotic cells
may not be good enough to allow an association between IIA and the now majority anionic
phospholipids membrane. In early apoptotic cells, IIA has also been found to interact with
anionic heparan sulfate proteoglycans and other specific cell surface receptors such as
vimentin through receptor ligand interactions (23). Both of these mechanisms of apoptotic
10

cell interaction with IIA sPLA2 are possible explanations of how IIA mediated hydrolysis
of membrane phospholipids occurs resulting in the production of fatty acids and
lysophospholipids that are capable of producing chemoattractant signals for phagocytic
uptake.

11

Hypothesis
Based on previous reports by Boilard and studies done in our lab, sPLA2 binds
preferentially to apoptotic cells via interaction with an unknown receptor. Once sPLA2
binds to the apoptotic cell and exerts a biological response, monocytes are able to migrate
to the dying cell. We hypothesize that the exposure of heparan sulfate proteoglycans on
apoptotic cells traps a pool of catalytically active sPLA2 that produces chemoattractant
lipids that recruit macrophages to phagocytose the apoptotic cells.

12

Materials and Methods
Cell culture: Jurkat cells were cultured in modified RPMI-1640 medium (Cellgro),
supplemented with 10% heat inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL
penicillin and 100ug/mL streptomycin, at 7.5% CO2, 100% humidity and 37ºC. THP-1
monocytes were cultured in modified RPMI-1640 medium (Cellgro), supplemented with
10% heat inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL penicillin and 100ug/
mL streptomycin, at 7.5% CO2, 100% humidity and 37ºC. Human Embryonic Kidney cells
(HEKs) were maintained in modified DMEM (Cellgro) supplemented with 10% heat
inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL penicillin and 100ug/mL
streptomycin, at 5% CO2, 100% humidity and 37ºC. Cell viability was determined by
Trypan Blue dye exclusion with a hemacytometer.

Induction of Apoptosis via antiFas: Fas-mediated apoptosis was induced by adding
20ng/mL CD95 (AntiFas, BD Pharmingen) to 1x106 cultured Jurkat cells/mL. Cells were
then incubated in 7.5% CO2, 100% humidity at 37ºC for varying time points (2, 4, 6, 8, 10,
12, 14, 16, 24 hours). Apoptosis was monitored through annexin-V binding and PI
staining (Vybrant apoptosis assay kit, Molecular Probes) followed by flow cytometric
analysis.

Induction of apoptosis via dihydrosphingosine: Apoptosis was induced by adding 10uM
DHS (obtained from Dr. Sarah Spiegel) to 1x106 cultured Jurkat cells/mL. Cells were then
incubated in 7.5% CO2, 100% humidity at 37ºC for varying time points (0, 2, 3, 4 hours).
13

Apoptosis was monitored through annexin-V binding and PI staining (Vybrant apoptosis
assay kit, Molecular Probes) followed by flow cytometric analysis.

Flow cytometric analysis of cell viability: Both treatment and control cells were
harvested and pelleted. After washing with PBS, the cells were re-suspended to a volume
of 1x106/mL 1X Annexin Binding Buffer (Vybrant apoptosis assay kit, Molecular Probes).
Solutions of 100ug/mL Propidium Iodide and FITC-Annexin V were prepared and each
was added to 100uL of the cells in 1X ABB (1uL and 5uL, respectively). The cells were
then incubated in the dark, at room temperature, for 15 minutes. Four-hundred microliters
(400uL) 1X ABB was added to the cells, and the final volumes were then stored on ice to
be later analyzed by a BD FACSCAN flow cytometer. Using CellQuest Pro software,
gates were set using control cells as the basis for determining normal, viable cells. Dot
plots produced showed the forward angle light scatter (FSC), which relates to the cell
diameter, versus the side angle light scatter, which relates the density of the inner cellular
structures. Annexin V-FITC staining helped to discriminate between apoptotic and nonapoptotic cells. Propidium iodide is a vital dye exclusion test which collects information
about the membrane integrity. Both were used to set quadrants to distinguish between nonapoptotic, early apoptotic, late apoptotic, and necrotic cells. Statistical analysis of the
different categories was determined using WinMDI.

Group IIa sPLA2 Plasmid Transfection: Mammalian expression vector encoding human
group IIa sPLA2 was obtained from Dr. Mike Gelb (University of Washington). Cultured
14

human embryonic kidney cells (500,000 cells/well) were transiently transfected via the
FuGENE 6 Transfection protocol (Roche) with the 1ug of the IIa plasmid to over express
the enzyme. After 36 hours of incubation at 5% CO2, 100% humidity at 37ºC, harvested
cultured supernatant was used as source of group IIa sPLA2.

Activity Assay: The measurement of enzymatic activity by group IIa was done utilizing
[3H] Oleic acid labeled E. coli cells as a substrate. Fifty microliters of culture supernatant
or acid extracted enzyme was incubated with ~65,000 cpm of E. coli cells in assay buffer
(25mM Tris-base, pH 9.0, 10mM calcium chloride, 5mg/mL fatty acid free bovine serum
albumin) along with 100 mg/mL FAF-BSA, and 1M CaCl2. Molecular Biology Grade
water was added to the enzyme/substrate mixture for a final volume of 500uL which was
incubated for 20 minutes at 37ºC. The addition of 250uL 2N HCL and 250 uL 20 mg/mL
FAF-BSA stopped the reaction and extracted free fatty acids, respectively. The volume
was incubated on ice for 20 minutes, then centrifuged at 7500 x g and 400uL of
supernatant was used for scintillation counting. The percent hydrolysis was assessed based
on counting the amount of released radiolabeled oleic acid (percent of input counts
released into supernatants).

Acid Extraction of Group IIa Secreted PLA2: Acid extraction of IIa sPLA2 denatures all
proteins but the IIa enzyme while also keeping the enzyme stable. After incubation with
DHS, 2x106 cultured Jurkat cells were re-suspended in 1mL PBS. Twenty-five microliters
of group IIa sPLA2 (culture supernatant from IIa Plasmid Transfection) was added to the
15

Jurkat cells and incubated on ice for 30 minutes (control cells contained no enzyme).
Treatment and control samples were then centrifuged for 20 minutes at 5000 x g. The
supernatant was discarded and the cell pellet was washed in 3mL PBS. To inactivate the
IIa enzyme, the pellet was re-suspended in 750uL of 0.36N sulfuric acid and left overnight
at 4ºC. The next day, the cells were centrifuged for 20 minutes and the supernatant was
saved and stored at 4ºC. The supernatant was used as an enzyme source and used in the
activity assay.

Production of Cell Chemoattractant: Early apoptotic and control cells were resuspended in PBS supplemented with CaCl2 at a concentration of 106 cells/mL. Twentyfive microliters of group IIa s PLA2 was added to the concentration of cells and incubated
on ice for 30 minutes. The cells were then incubated in a warm water bath at 37ºC for 20
minutes with the shaker at moderate speed. The cells were centrifuged at 7500 x g for 5
minutes and the supernatants were used as chemoattractants for the chemotaxis assay.

Chemotaxis Assay: Transwell plates (8um pore, Fisher) were used for the chemotaxis
assay. Both the upper and lower chambers of the wells were pre-incubated with 2% FCS
for 1 hour. After the removal of the 2% FCS medium, 300uL of chemoattractant along
with 300 uL of 2% RPMI was placed in the lower chamber of the transwell. One-hundred
microliters (100uL) of THP-1 monocytes, which were previously cultured to 1x106/mL,
were added to the upper chamber of the transwell. The wells were incubated for 2 hours at
37ºC. After 2 hours the contents of each chamber were transferred to separate Falcon
16

tubes for analysis of migration by the Beckman Coulter Cytomics FC 500 Series flow
cytometer. Percent chemotaxis was calculated as percent of total cells migrated to the
lower chamber.

Para-bromophenacylbromide (BPB) Inactivation of IIa sPLA2: Three milliliters
(3mL) sPLA2 enzyme was incubated with 200mM BPB (in PBS with EtOH as a cosolvent) on ice for 30 minutes. For removal of residual BPB, both the treatment and
control samples were dialyzed against PBS for 16 hours at 4ºC using 3.5K dialysis tubing.
The dialyzed enzymes were then tested for catalytic activity using the activity assay. The
dialyzed enzymes were also used as a source of IIa sPLA2 in a modified cell
chemoattractant production assay.

Blockage of Heparan Sulfate Proteoglycan binding sites on sPLA2 via Heparin:
Heparin was used in solution with sPLA2 to see if sPLA2 was able to bind to heparan
sulfate proteoglycans on the surface of Jurkat cells and exert catalytic activity. Two
million Jurkat cells were cultured and re-suspended in one milliliter of different heparin
concentrations (500ug, 250ug, or 50ug/mL PBS). The acid extraction assay was
performed and catalytic activity was assessed via the activity assay. The percent
hydrolysis was assessed (percent of input counts released into supernatants).

Heparinase III activity assay: Jurkat cells were incubated in 50mU/mL heparinase III for
5 hours at 37ºC ( 2x106 Jurkat cells/mL heparinase). The cells were then re-suspended in
17

1mL PBS. The acid extraction assay was performed and catalytic activity was assessed via
the activity assay. The percent hydrolysis was assessed (percent of input counts released
into supernatants).
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Statistical Analysis: Data shown are mean and standard deviation of multiple
experiments done in triplicate or other replicate noted. Statistical significance was
determined by using the student’s t-test with p < 0.05.
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Results
Figures 1 and 2.
Forward scatter by side scatter analysis along with propidium iodide and annexin vFITC staining shows Jurkat cells are viable and mainly non-apoptotic. One million
Jurkat cells were grown under cell culture conditions without the presence of
dihydrosphingosine. Cells were stained with propidium iodide and annexin v-FITC and
analyzed with a flow cytometer. Forward scatter vs Side Scatter: Dead cells are located in
R0 and live cells are in R1. UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late
apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-); LR (early
apoptotic) : PI (-), Annexin V-FITC (+). Experiment was repeated in triplicate, with this
being the single representative experiment.
0 hours FSC/SSC

0 hours PI/Annexin-V FITC

Figure 1

Figure 2
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1.03
7.4
88.94
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Figure 3 and 4.
Incubation of Jurkat cells with dihydrosphingosine for 2 hours shows initial
progression into early apoptosis. One million Jurkat cells were incubated for two hours
in the presence of DHS. The Jurkat cells were stained with propidium iodide and annexin
v-FITC and analyzed with a flow cytometer. Forward scatter by side scatter dot plot
shows the population of live cells in R1 and dead cells in R0. Annexin-V/FITC staining
shows cell progression into apoptosis. UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late
apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-); LR (early
apoptotic) : PI (-), Annexin V-FITC (+). Experiment was repeated in triplicate, with this
being the single representative experiment.
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Figure 5 and 6.
Effect of three hour incubation of Jurkat cells with dihydrosphingosine via foward
scatter by side scatter analysis and propidium iodide and annexin –v/FITC staining
shows a decrease in the population of viable cells. One million Jurkat cells were
incubated for three hours in the presence of DHS. The Jurkat cells were stained with
propidium iodide and annexin v-FITC and analyzed for apoptotic progression with a flow
cytometer. Forward scatter by side scatter dot plot shows the population of live cells in R1
and dead cells in R0. UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late apoptotic): PI
(+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-); LR (early apoptotic) : PI
(-), Annexin V-FITC (+). Experiment was repeated in triplicate, with this being the single
representative experiment.
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Figure 6

Region

% total

% gated

R1

53.86

53.86

R0

46.14

46.14

QUAD
UL
UR
LL
LR

22

% TOTAL
0.09
44.57
8.62
46.72

% GATED
0.09
44.57
8.62
46.72

Figure 7 and 8.
Jurkat cells incubated with dihydrosphingosine for four hours and analyzed with
forward scatter by side scatter flow cytometry show equal populations of viable and
dead cells. Annexin-V/FITC and propidium iodide staining show a majority of cells
in early or late apoptosis. One million Jurkat cells were incubated for four hours in the
presence or absence of DHS. The Jurkat cells were stained with propidium iodide and
annexin v-FITC and analyzed with a flow cytometer. UL (necrotic): PI (+), AnnexinVFITC (-); UR (late apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin VFITC (-); LR (early apoptotic) : PI (-), Annexin V-FITC (+). Forward scatter by side
scatter dot plot shows the population of live cells in R1 and dead cells in R0. Experiment
was repeated in triplicate, with this being the single representative experiment.
4 Hours SSC/FSC

4 Hours PI/Annexin V FITC

Figure 7

Figure 8
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Flow cytometric forward by side scatter analysis shows live and dead cell populations:
According to Boilard, early apoptotic cells are preferentially bound by sPLA2, possibly
because of the exposure of PS and vimentin (23). Jurkat cells were made early apoptotic
via DHS because it has the ability to quickly induce cell apoptosis without increasing
necrotic cell death (20). For our experiment we wanted to generate a population of early
apoptotic cells. The gated region of the plot refers to the population of cells that were
analyzed as being live, early apoptotic, late apoptotic, or necrotic (Figures 2, 4, 6, and 8).
Dot plots produced show the forward angle light scatter (FSC), which assesses the cell
diameter, versus the side angle light scatter (SSC), which relates to the density of the inner
cellular structures (Figures 1, 3, 5, and 7) (26). The R1 region includes vital cells while the
R0 (non-gated) region is necrotic/apoptotic cells. As apoptosis occurs, the cell shrinks, and
the forward angle light scatter population decreases. This correlates with an increase in
side scatter, which is an increase cytoplasmic granularity. When apoptotic analysis is
applied to flow cytometric gated regions, cells displaying a progression in apoptosis
exhibit a decrease in the R1 population and an increase in the R0 population (26).
For the shown dot plots, as cells are incubated with DHS for longer time points, the
percentage of cells in the gated regions decreases for region 1 and increases for region 0.
Jurkat cells incubated with no DHS show a 90.3% viability. Jurkat cells incubated with
DHS for 2, 3, and 4 hours show a decrease in cell viability as shown by 80.3%, 53.9%,
50% viability, respectively. The decrease in cell viability and the decrease in the
population of cells in R1 suggest cells are shrinking in size and possibly going through
apoptosis. Jurkat cells located in the non gated region are classified as necrotic or apoptotic
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cells. An increase in the incubation time of cells applied with DHS show an increase in the
population of apoptotic or necrotic cells. Control Jurkat cells containing no DHS show
9.7% of the cells being in the R0 region. Jurkat cells incubated with DHS for 2, 3, and 4
hours show an increase in the side scatter population region producing 19.7%, 46.1%, and
50% of cells in apoptosis or necrosis respectively. By the fourth hour of incubation in
DHS, there were approximately equal populations of cells in both regions. The overall
increase in side scatter percentages and decrease in forward scatter percentages suggests
the Jurkat cells are dying.
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Use of Propidium Iodide and Annexin V- FITC after Jurkat cell incubation with
dihydrosphingosine differentiates live, early apoptotic, late apoptotic, and necrotic cells
via flow cytometric analysis: Jurkat cells were stained with both propidum iodide (PI) and
annexin v-FITC (AVF) after incubation with or without DHS. Propidium iodide is
generally membrane impermeable and stains DNA in leaky cells. It is ultimately used as a
vital dye exclusion test between viable and dead cells, similar to trypan blue (27).
Annexin-FITC staining is used as a test to determine apoptotic progression; distinguishing
between apoptotic and non- apoptotic cells. Annexin-FITC is found to bind to anionic
phospholipids such as phosphatidylserine which flips to the outer leaflet of cells during
early apoptosis (27).
Quadrants were set for the dot plots comparing propidium iodide staining to
annexin V-FITC staining (Figures 2, 4, 6, and 8). The lower left (LL) quadrant designates
live, viable cells, the lower right (LR) quadrant applies to early apoptotic cells, the upper
right (UR) quadrant applies to late apoptotic cells, and the upper left (UL) quadrant applies
to necrotic cells. Jurkat cells in the LL quadrant are both PI and AVF negative, Jurkat cells
found in the LR quadrant are PI negative and AVF positive, Jurkat cells found in the UR
quadrant are both PI and AVF positive, and Jurkat cells found in the UL quadrant are PI
positive and AVF negative. Both the lower right and lower left quadrants are viable cells
which relate to the R1 region while the upper right and upper left quadrants are necrotic
and apoptotic cells which relate to the R0 region. Since we were interested in the overall
generation of early apoptotic Jurkat cells, the lower right quadrant will be the most
important quadrant in this study. We will be comparing control cells to cells incubated in
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DHS for four hours because the four hour time point analysis of annexin-V versus PI has
the largest ratio of early apoptotic cell population compared to control cell population
(Figures 1 and 2 versus Figures 7 and 8). The total population of cells were analyzed (R1
and R0). The four hour incubation alone also has the smallest ratio of early apoptotic
versus late apoptotic cells (1 fold). Analysis of the lower left quadrant for each time point
shows a negative relationship between the incubation time of cells with DHS and the
reduction of live cells. There is a fifty-five fold decrease in live cells located in the LL
quadrant when control cells are compared to cells incubated for 4 hours in DHS (88.9% to
1.6%). The lower right quadrant, which contains the population of cells we are most
interested in, shows a nineteen fold increase in the population of early apoptotic cells
(2.6% to 50%). The population of late apoptotic cells in the upper right quadrant exhibit a
6.5 fold increase from 7.4% in control cells to 48% in cells incubated with DHS for four
hours. The Jurkat population located in the upper left quadrant, which designates necrotic
cells, shows a 3 fold decrease (1% to 0.35%). This is probably attributed to cells which
were dead before the DHS was applied, as seen by similarly low necrotic percentages in all
other time points. Overall there is a negative correlation between cell viability and DHS
incubation time. When the DHS incubation time increases from two hours (63.5% viable
cells in LL), 3 hours (8.6% in LL), and 4 hours (1.6% in LL), there is an increase in the
population of early apoptotic cells from 2, 3, and 4 hours (17.6%, 46.7%, 50%,
respectively in the LR quadrant). Ultimately, as Jurkat cells are incubated for longer times
in DHS, cell viability decreases.
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Figure 9.
Cultured supernatant from sPLA2 IIA transfected HEK’s used as a source of group
IIa sPLA2 are shown to exhibit enzymatic activity. Human embryonic kidney cells were
transiently transfected with group IIA sPLA2 vector plasmids or control in DMEM as
described in the material and methods. Cultured supernatants were harvested after 36
hours and enzymatic activity was calculated based on percent hydrolysis of released
radiolabeled oleic acid. Results are a single representative experiment done in triplicate.
Human embryonic kidney cells transfected with IIA vector plasmid produces culture
supernatant that has phospholipase activity: To generate a source of IIA sPLA2, a cultured
supernatant produced from HEK transfection was used in our experiments. Human
embryonic kidney cells were transiently transfected with a mammalian expression vector
encoding human group IIa sPLA2 and enzymatic activity of the phospholipase was found
to have 26.1% hydrolysis of the substrate. The control, which contains an enzyme source
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that was made by transfected HEK’s in the absence of group IIa sPLA2 plasmids, shows a
0.7% hydrolysis of the substrate. The blank contains no enzyme, and exhibits a 0.003%
non enzymatic hydrolysis of the substrate. There is a 37 fold increase in hydrolysis when
the control is compared to the group IIa enzyme.
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Figure 10.
Catalytically active group IIa sPLA2 enzyme binds control and DHS treated-early
apoptotic cells equally with no specific preference. Jurkat cells incubated in the
presence of DHS or absence of DHS were harvested after four hours. Different volumes of
group IIa sPLA2 was added exogenously to the Jurkat cells. An acid extraction was
performed on the cells as explained in material and methods, and the percent hydrolysis
was assessed. Data shown is from four compiled experiments done in triplicate.
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Catalytically active group IIa sPLA2 enzyme binds control and DHS treated-early
apoptotic cells equally: As previously mentioned, sPLA2 has a preference for anionic
phospholipids such as PS and PE, which are seen on cell surfaces during early apoptosis
(18). Live and apoptotic cells have a difference in the kinds of phospholipids and receptors
available on their cell surfaces. Comparison of control cells and cells treated with DHS in
the PI/AVF analysis show a 19 fold increase in the population of early apoptotic cells.
According to previous findings, early apoptotic cells bind to sPLA2 with a greater
preference than non-apoptotic cells because the sPLA2 is attracted to the anionic
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phospholipids which flip to the outer membrane during apoptotic progression. We wanted
to see if there was a difference in the ability of IIA to hydrolyze exposed phospholipids on
live or early apoptotic cells. The results in figure ten show that regardless of the volume of
sPLA2 incubated with Jurkat cells, there is no statistically significant difference of enzyme
activity between the group IIa sPLA2 cell bound extracts from either the control group or
the early apoptotic population of cells. Apoptotic cells incubated with IIA supernatant
produced extracts that had statistically significant differences in the ability to hydrolyze
substrate in a dose dependent manner. However, extract received from live cells incubated
with IIA had no statistically significant differences in the ability to hydrolyze substrate in
correlation to the increased sPLA2 volumes. The only extracts (for both apoptotic and nonapoptotic cells) that proved to be statistically relevant when assessing the percent
hydrolysis were the extracts produced from cells that had been incubated with one-hundred
microliters of sPLA2. Though the extracts produced from cells incubated with 100
microliters sPLA2 demonstrated a hydrolysis percentage that was statistically different
when compared to the other samples, there was still no difference in the ability of sPLA2
to hydrolyze phospholipids on control or early apoptotic cells. There was a dose
dependent increase in enzymatic activity as the amount of exogenous sPLA2 added to cells
increased, but there was no statistically significant difference in enzymatic activity
between control or early apoptotic cell extracts. Similar hydrolysis activity suggests that
sPLA2 binds non apoptotic and control cells with same specificity. Based on previous
reports from Boilard, we expected there to be a significant difference between the
interaction of sPLA2 on apoptotic and non apoptotic cell populations, with the early
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apoptotic cells exhibiting higher enzymatic activity, but our results proved otherwise.
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Figure 11.
Pool of catalytically active group IIa sPLA2 “trapped” on the surface of Jurkat cells
generates chemoattractants which cause THP-1 monocyte chemotaxis directly or
indirectly. sPLA2 culture supernatant was exogenously added to live Jurkat cells and a
chemoattractant was produced using the chemoattractant protocol as stated in materials and
methods. Twenty-five microliters of sPLA2 culture supernatant was incubated with Jurkat
cells and the resulting chemoattractant/extract produced was placed in the bottom chamber
of a transwell along with 2% RPMI 1640 medium until the final volume reached 600uL.
The negative control was generated from Jurkat cells that were incubated with no sPLA2.
One hundred THP-1 monocytes were added to the top chamber of the transwell and after 2
hours the percent of THP-1 monocytes that migrated from the top chamber to the bottom
chamber was calculated from three replicates. Data shown is from a single representative
experiment.
Catalytically active sPLA2 IIA trapped on Jurkat cell surfaces produces a chemoattractant
which causes THP-1 monocytes to migrate in a dose dependent manner
: The products generated from the hydrolysis of phospholipids by sPLA2 are fatty acids
and lysophospholipids. Examples of these products include LPC and AA which are both
known chemotactic mediators (9). Since we previously noted that there was no difference
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in the ability of IIA to bind live or non-apoptotic cells, this experiment was done to see if
IIA bound to live Jurkat cells had the ability to generate chemoattractants that attracted
THP-1 monocytes. Transmigration was performed by adding THP-1 monocytes to the
upper chamber of a transwell and different amounts of chemoattractant in the lower
chamber of the transwell. The migration of THP-1 monocytes from the upper chamber to
the lower chamber was calculated as percent of THP-1 monocytes transmigrated. The
assay was found to have a positive dose dependent increase correlating to the migration of
THP-1 monocytes; as the volume of chemoattractant increased in the bottom chamber, the
percentage of migrated monocytes increased. The percentage of monocyte chemotaxis in
the negative control showed no statistically significant differences as the amount of extract
in the bottom transwell changed. There was a dose dependent increase in the amount of
THP-1 migration, but as stated previously there was no statistically significant difference
when comparing the extracts (excluding 0 microliters). For the samples containing
chemoattractant produced from incubation of Jurkat cells with sPLA2, the control had 1.6%
of the THP-1 monocytes migrate from the upper chamber to the lower chamber. The
treatment sample containing 100uL chemoattractant in the lower chamber had a 6.3%
migration, but was not statistically significantly different from the control. The 200uL
treatment had a 14.6% migration, and the 300uL treatment had a 37.8% migration of
monocytes. The treatment containing 300uL chemoattractant had the largest fold
difference (24 fold) in comparison the control and was ultimately used as the basis for the
amount of chemoattractant used in all other assays involving chemotaxis.
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Figure 12.
Group IIa sPLA2 generates soluble bioactive molecules which induce THP-1
monocyte chemotaxis directly or indirectly in both anti-Fas induced apoptotic cells
and non apoptotic cells. Control and antifas-treated Jurkat cells were harvested at 12hrs
and processed to obtain cell supernatants for chemotaxis as described in methods. Six
hundred microliters of 10 nM MCP-1 prepared in 2% FCS RPMI 1640 medium, and 100
uL of possible chemoattractant for samples IIa only, F-,F+, and C+ was added to 500 uL of
2% FCS RPMI 1640 medium and placed in lower chamber of transwells. All samples
received 100,000 THP-1 monocytes in upper chamber. (+)= with IIa, (-)= without IIa.
Group IIa sPLA2 generates soluble bioactive molecules which induce THP-1 monocyte
chemotaxis directly or indirectly : Since sPLA2 added to non-apoptotic cells was found to
generate a chemoattractant, we wanted to see if there was a difference in the
chemoattractants produced from non-apoptotic versus apoptotic cells and their ability to
induce monocyte chemotaxis. We did this experiment using anti-Fas and not DHS because
we were trying to confirm and extend Boilard’s work (18, 23). Monocyte Chemotactic
Protein-1 is a potent β-chemokine that recruits monocytes and promotes cell adhesion and
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transmigration across an endothelial layer into tissue via a PKC signaling pathway. The
MCP-1 was used as a positive control to compare potency of the group IIa sPLA2 products
as chemoattractants. Supernatants of both the control and anti-fas cells treated with IIa
sPLA2 contained a chemotactic factor which was equally as effective as MCP-1 in
recruiting THP-1 monocytes. On the other hand, supernatant of anti-fas treated cells
without group IIa sPLA2 treatment minimally affected transmigration of monocytes and
was about 50% less compared to MCP-1. Also group IIa sPLA2 alone had no affect on
chemotaxis. These data suggest that sPLA2 acts on Jurkat cells to generate
chemoattractants (28).
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Figure 13.
BPB inactivation of group IIa sPLA2. Dead enzyme was generated to see if catalytic
activity as required for chemotaxis. sPLA2 culture supernatant was incubated with 200mM
para-bromophenacylbromide for 30 minutes, then dialyzed against PBS using 3.5K
dialysis tubing. The inhibited enzyme was tested for catalytic activity using the activity
assay as described in methods. Data shown is single representative experiment, done in
triplicate.
BPB is able to inhibit the catalytic activity of IIA sPLA2: Para-bromophenacylbromide is
an irreversible inhibitor of sPLA2 that does not inhibit other forms of PLA2. A source of
catalytically inactive enzyme needed to be made to see if enzyme activity was required for
chemotaxis. Analysis of catalytic activity shows that BPB inhibits sPLA2. Catalytic
activity is shown to cease when the enzyme is treated with BPB. The BPB treated enzyme
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has a percent hydrolysis below control which means that the enzyme had no affect on the
hydrolysis of glycerophospholipids located in the radiolabeled oleic acid substrate. The IIa
enzyme, which was treated with a vehicle (PBS), still showed high catalytic activity by
hydrolyzing 13.1% of the substrate.
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Figure 14.
Monocyte chemotaxis is independent of sPLA2 activity. Two million live Jurkat cells
were suspended in 1 milliliter of PBS and incubated with 60 uL BPB treated enzyme, or
vehicle treated enzyme for thirty minutes on ice. Another sample, containing no Jurkat
cells, was also incubated with BPB treated enzyme for thirty minutes on ice. The
chemoattractant protocol was followed with the resulting chemoattractants used in the
chemotaxis assay. The average fold change was calculated using the fold changes from
each experiment. The fold changes were calculated by getting the ratio of the percentage
of THP-1 monocytes migrated from the upper chamber to the lower chamber in treated
samples (vehicle, bpb, no Jurkat cells) versus the control samples which contained no
chemoattractant. Data shown is average of six experiments done in triplicate.
Catalytically active sPLA2 is not required for monocyte chemotaxis: sPLA2 IIA produces
possible chemoattractants via catalytic hydrolysis of anionic phospholipids. If catalytic
activity of the enzyme is inhibited, we hypothesize an abolishment of monocyte
chemotaxis. The effect of catalytic activity on THP-1 monocyte migration was tested.
Based on the results provided, THP-1 monocytes are able to migrate regardless of enzyme
activity. There was a 2.64 fold average increase in the amount of THP-1 monocytes that
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migrated when using the enzyme dialyzed against the vehicle as a chemoattractant, in
comparison to the control. THP-1 monocytes that migrated using BPB inactivated enzyme
had a 2.45 fold average increase in comparison to the control. Statistically, there is no
significant difference between the two treatment samples. When there are no cells present
during the chemoattractant production, there is a 0.40 fold difference when compared
against the control. sPLA2 activity is not required for optimal chemotaxis; the whole
response is independent of catalytic activity. This observation suggests that the enzyme
may stimulate Jurkat cells to produce chemoattractants through binding to heparan sulfate
proteoglycans, the M-type receptor, or other cell surface receptors. Also, the source of
bioactive lipids, which produce the chemoattractants, could be produced intracellularly by
other PLA2’s such as iPLA2 or cPLA2.
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Figure 15.
Addition of heparinase drastically prevents sPLA2 binding to Jurkat cell surfaces.
Two million Jurkat cells were incubated in the presence or absence of 50uM heparinase for
5 hours. Group IIA sPLA2 was exogenously added to the cells after they were washed and
re-suspended in PBS. The acid extraction protocol was followed and percent hydrolysis
was calculated with from the average of four different experiments done in quadruplicate.
Addition of heparinase III prevents sPLA2 IIA substrate hydrolysis: Heparinase cleaves
cell surface heparan sulfate proteoglycan chains. sPLA2 is thought to bind to these heparan
sulfate proteoglycan chains in a receptor ligand interaction. If the HSPG are able to trap a
pool of catalytically active sPLA2, hydrolysis of cell surface phospholipids may occur.
Once sPLA2 binds to the HSPG receptors, it is in a position close enough to cell surface
glycerophospholipids. The new position may ultimately allow for hydrolysis of the cell
surface glycerophospholipids to produce fatty acids and lysophospholipids. This
experiement was done in order to identify a possible enzyme receptor. Jurkat cells that
were not incubated in heparinase show a 6.63% hydrolysis of the substrate whereas cells
that were incubated in heparinase have a 0.45% of hydrolysis. The 15 fold decrease in
group IIA’s ability to hydrolyze cell surface phospholipids when heparinase is present,
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suggests heparan sulfate proteoglycans act as a receptor to trap the enzyme on the cell
surface. When these “receptors” are cleaved, sPLA2 has no receptor to bind to, which
means it can no longer access the phospholipids located on the cell surface and hydrolyze
them.
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Discussion
We hypothesized that group IIA secretory phospholipase A2 preferentially binds to heparan
sulfate proteoglycan chains exposed on early apoptotic cells ultimately generating lipid
chemoattractants that mediate THP-1 monocyte chemotaxis. The guideline for our study
was based on previous studies done by Boilard and his colleagues. They examined the
interaction between group IIA sPLA2 and early apoptotic induced via anti-Fas. Apoptosis
is characterized by dramatic disruption to the cellular structure that contributes to
programmed cell death and also prepare cells for removal by phagocytes for prevention of
unwanted immune responses (2). Based on previous studies done by Boilard and his
colleagues, T-cells were induced to undergo apoptosis via anti-Fas (18). Antigen driven Tcell apoptosis involves Fas, the cognate cell surface receptor that interacts with the death
cytokine Fas ligand to assemble caspase-activating protein complexes which ultimately
lead to programmed cell death (19). Our studies induced early apoptosis via D, L-threodihydrosphingosine (DHS). DHS is a sphingosine kinase inhibitor which induces
apoptosis without significantly increasing necrotic cell death. Apoptotic cells have been
found to induce the expression of sphingosine kinase 1 to release sphingosine-1-phosphate
which acts as a recognition and uptake signal for cells to phagocytose (20). Jurkat cells
incubated with 10uM/mL DHS for 0, 2, 3, and 4 hours showed a gradual progression into
apoptosis via analysis of forward scatter/side scatter dot plots (Figures 1, 3, 5, and 7).
Forward angle light scatter relates to the cell diameter while side angle light scatter relates
to the density of inner cellular structures. As apoptosis occurs, the cell shrinks, and the
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forward angle light scatter population decreases. This correlates with an increase in side
scatter population which is an increase in the density of cellular structures. To further
verify that the Jurkat cells were undergoing apoptosis they were stained with both
propidium iodide and annexin-V FITC and defined as “live”, early apoptotic, late
apoptotic, or necrotic. Annexin binds negatively charged phospholipids in a calcium
dependent manner while propidium iodide, which is generally membrane impermeable,
stains DNA in leaky cells (3). There was a nineteen fold increase in the ratio of early
apoptotic cells which had previously been incubated in DHS for four hours compared to
Jurkat cells incubated in vehicle for the same amount of time (Figures 7 and 8). Human
embryonic kidney cells transfected with group IIA sPLA2 vector plasmids were found to
show significant catalytic activity (Figure 9). Different volumes of IIA sPLA2 culture
supernatant produced from the transfected HEK cells was exogenously added to treated
and control cells. Contrary to previously published studies by Boilard and his collagues,
early apoptotic cells did not preferentially bind sPLA2 IIA when compared to control cells.
Statistically speaking there was no significant difference between the two groups (Figure
10). This was surprising because in most mammalian cells, anionic phospholipids
segregate preferentially in the inner leaflet of the plasma membrane bilayer, and this leaves
the outer leaflet with very little net charge which sPLA2 should disfavor because of the ring
of cationic residues on its interfacial binding surface (16). Based on the annexin-V binding
experiment we performed, PS was definitely exposed on the treatment cells so the IIA
enzyme should have preferentially bound to the early apoptotic cells because of the
increased exposure of PS. The IIA enzyme is known to have a low affinity for the plasma
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membrane of normal host cells because of the zwitterionic nature of their outer monolayer
(21). When this happens there are lower rates of membrane hydrolysis observed, as seen
in Figure 10. A recent study has shown that the rod domain of vimentin, a type III
intermediate filament protein, is externalized in early apoptotic cells during the same time
as PS exposure. Vimentin creates a receptor for IIA in a calcium independent manner (23).
This concludes that IIA is most likely not binding to phosphatidylserine alone and if it is, it
does not play a major role in trapping the enzyme on the cell surface.
Though there were negligible differences between rates of hydrolysis seen when
IIA culture supernatant was incubated with treatment and control cells, IIA was able to
produce a chemoattractant that induced THP-1 monocyte chemotaxis (Figure 11). There
was a dose dependent increase in the number of THP-1 monocytes that migrated from the
upper chamber the lower transwell chamber as the volume of chemoattractant in lower
chamber increased. Comparison of migration of THP-1 cells with no chemoattractant
versus the migration of cells with three hundred microliter chemoattractant in the lower
chamber showed a 24 fold increase in the number of migrated cells. However, there was
still no significant difference noted between untreated or early apoptotic Jurkat cells ability
to generate chemoattractants. When compared to MCP-1 there was no significant
difference in the population of THP-1 monocytes that migrated when compared to treated
and untreated cells incubated with culture supernatant. (Figure 12). This suggests that
when sPLA2 IIA binds to treated or untreated cells, they both produce chemoattractants
that are just as effective as MCP-1. Jurkat cells are known to contain about forty percent
PC on the outer leaflet of their plasma membrane. LPC could possibly be generated by
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sPLA2 via catalytic hydrolysis of phosphatidylcholine (6). LPC is generated upon
phospholipase A2 mediated hydrolysis of membraneous phosphatidylcholine into LPC and
a fatty acid such as arachidonic acid (6). To determine if catalytic activity was required for
monocyte chemotaxis, IIA culture supernatant was catalytically inactivated with parabromophenacylbromide (BPB) and added to live cells to produce a possible
chemoattractant. Upon catalytic analysis, BPB inhibited the catalytic activity of IIA
(Figure 13). Hydrolysis of substrate phospholipids via sPLA2 proceeds through the
activation and orientation of a water molecule by hydrogen bonding to the active site
histidine, which dictates the pH dependence of 7-9 for all PLA2’s with a catalytic histidine
(8). sPLA2 completely loses its catalytic activity when the imidazole side chain of
histidine 53 is alkylated through the reaction with BPB. BPB is a selective inhibitor of
sPLA2 only, so catalytic activity can possibly be attributed to the activation of caspase-3.
Caspase-3 has been found to be required for the release of lysophosphatidycholine from
the subsequent activation of iPLA2 though catalytic activity can be exerted via iPLA2 and
cPLA2 without caspase activation (17). Monocyte chemotaxis was found to be independent
of sPLA2 activity. THP-1 monocytes were able to migrate to chemoattractants regardless of
enzymatic activity; suggesting that the enzyme may stimulate Jurkat cells to produce
chemoattractants through binding to heparan sulfate proteoglycans or other cell surface
receptors (Figure 14). The addition of heparinase to Jurkat cells before they are treated
with IIA culture supernatant shows a decrease in the ability of IIA to exert catalytic
activity when compared to the control. This suggests heparan sulfate proteoglycans
possibly act as a receptor to trap the enzyme on the Jurkat cell surface. When these
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receptors are cleaved (done with heparinase), the sPLA2 has no receptor to bind which
means it can no longer access the phospholipids located on the cell surface or internally
and hydrolyze them (Figure 15). Based on our results from our experiments we can
conclude sPLA2 most likely associates with cells through interactions with heparan sulfate
proteoglycans or another type of receptor. Additional experiments are necessary to
confirm lack of chemoattractant production in heparinase treated cells.
Heparan sulfate proteoglycans participate in many events during cell adhesion,
migrations, proliferation, and differentiation (24). Cell surface heparan sulfate
proteoglycans typically contain N linked and O linked oligosaccharides as carbohydrate
components. They are primarily localized in the plasma membranes or basement
membranes. HSPG such as glypican, decorin, and versican, are associated with the plasma
membrane via direct intercalation of the core protein into the lipid bilayer, intercalation
through a glycosylphosphatidylinositol (GPI) anchor covalently bound to a core protein, or
specific or relatively nonspecific interactions between heparan sulfate chains and other
molecules associated with the plasma membrane. Glypican, is anchored to the external
surface of the plasma membrane via GPI. Heparan sulfate chains such as the three seen on
glypican, are highly negative which determine their interactions with extracellular ligands
(15). Following binding of the highly anionic HSPG to the highly cationic IIA sPLA2,
there are a number of endocytic routes available to allow internalization of the enzyme.
IIA can be internalized via clathrin mediated endocytosis or caveolae mediated endocytosis
where the enzyme is allowed to produce biological responses(21). Based on observations
of experiments done by Birts and his colleagues, the IIA enzyme is able to be taken up by
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activated human THP-1 cells in an energy dependent process that relies on HSPG and
involves macropinocytosis. Uptake of the enzyme does not require the enzyme to be
active, which could explain why BPB treated and untreated enzymes produced
chemoattractants with similar migration percentages. Birts also discovered the enzyme
accumulates to the nucleus and is also able to bind and aggregate anionic phospholipids
vesicles enhancing its uptake (21, 23). sPLA2 IIA has been found to accumulate in the
caveolae and perinuclear sites, rather than being distributed uniformly on the cell surfaces
as previously thought when associating with heparan sulfate chains of the GPI anchored
HSPG glypican (3, 24). After IIA is sorted into different compartments (via HSPG
shuttling pathway), the enzyme is concentrated into the restricted compartments which
allows for a spatial and temporal colocalization with perinuclear arachidonic acid
metabolizing enzymes such as the overexpressed cyclooxygenase, COX-2 and 5lipoxygenase for efficient eicosanoid production (3). Murakami, found via confocal
microscopy, that after IIA is internalized, there may be perinuclear hydrolysis of
membrane phospholipids. If there is in fact hydrolysis of membrane phospholipids, the
products produced would definitely provide chemoattractants such as LPC, LPA., and AA.
Secretory phospholipase A2 could also bind to its probable heparan sulfate receptor and
induce production of a protein chemokine such as monocyte chemotactic protein-1. If IIA
is colocalized with COX-2 the eicosanoids produced are also important stimulators for cell
migration (24). Boilard noted, that when he added heparin and heparinase to apoptotic
cells, IIA binding was only partially inhibited, suggesting that there were other binding
proteins involved with sPLA2 allocation on cell surfaces besides heparan sulfate
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proteoglycans (18).
sPLA2 is able to interact with external cell membranes through direct binding to
phospholipids or specific cell surface receptors (23). Human high affinity cell surface
receptors for the human group IIA enzyme have yet to be identified (21) but the interaction
of IIA with the M type receptor is proposed as the main mechanism of action explaining
the effects of IIA in mast cells and macrophages. The M type receptor is a novel
membrane bound protein found in skeletal muscles with structural organization similar to
the C-type multilectin mannose receptor family (22). The domain of the M type receptor
that is responsible for sPLA2 binding, is the carbohydrate recognition domain 5. An M-type
receptor where all CRD’s but CRD5 have been deleted can still bind sPLA2 with great
affinity (22). Since this has only been found using mouse IIA sPLA2, this suggests all
receptors have not been characterized. Like HSPG, a common property of the C-type
multilectin mannose receptor family is endocytosis; and it has been proposed that the
physiological role for the M type sPLA2 receptor is to internalize and deliver the sPLA2
group IIA to specific compartments within the cell where the enzyme may exert its
activity (12). Our usage of heparinase blocks most of our monocyte chemotactic activity,
suggesting that there may not actually be a need for an additional receptor.
Our studies have shown that sPLA2 is able to bind both apoptotic and non apoptotic
cells in the same fashion, creating a potent supernatant that attracts THP-1 monocytes
regardless of catalytic activity. Cleavage of heparan sulfate proteoglycans on cells applied
with exogenous IIA sPLA2 prevent sPLA2 from binding and exerting catalytic activity,
suggesting HSPG play an important roll in trapping a pool of the enzyme. sPLA2
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definitely plays a role in monocyte chemotaxis, but it has yet to be established if it does
this by direct interaction with monocytes, indirectly via interaction with intracellular
pathways, or both. Phagocytosis requires multiple signals from apoptotic cells and these
studies show sPLA2 have importance in producing these signals. Since IIA applied to non
apoptotic cells was found to also produce chemoattractants, this could prove to be an
important factor in dealing with cancer cells and their subsequent removal. In future
studies, we will try to identify specific IIA receptors and see is HSPG is required for
monocyte chemotaxis.
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